

GLOBAL SUSTAINABLE OUTCOMES

News & Views Q1 2020



Pauline Grange
Portfolio Manager,
Global Equities



Jess Williams
Portfolio Analyst,
Responsible Investment

This quarter has marked the end of the longest bull market in history after a decade-long recovery since the global financial crisis. Entering 2020, nobody would have predicted the “black swan” event that was to come, providing a lethal shot to both the financial markets and global economies.

Since a new SARS-(severe acute respiratory syndrome) related virus was first reported in Wuhan in December under the name SARS-CoV-2, it has dominated global headlines. Although markets have recovered from the initial sell-off, which was the fastest in history, uncertainty remains both in terms of the path of the virus and that of economic recovery.

The Global Sustainable Outcomes (GSO) strategy has navigated this crisis well, benefiting from our focus on quality companies with solid environmental, social and governance (ESG) credentials and financial liquidity. This saw the strategy falling -14.7% vs the MSCI World decline of -21.3% from 31 December 2019-31 March 2020 – an 8.3% outperformance.¹

More importantly, several of our investments made a strong impact during this crisis. The largest sustainable theme within GSO is that of health, wellbeing and food security, accounting for roughly 27% of our holdings. This pandemic has served to highlight the importance of medical innovation and good health.

Medical technology has accelerated in recent years and this has been clearly on display during this crisis with the rapid progress made with both the development of vaccines as well as therapeutic treatments targeting the virus. The genome of the disease was mapped by mid-January and there are 70+ vaccine programmes underway. In the past this would have taken years not weeks to achieve.



Medical technology has seen rapid progress in developing a vaccine. Source: iStock/Getty Images International.

Several of our healthcare holdings² have made a positive contribution, including:

- **Gilead** (a world leader in antiviral/anti-inflammatory medicines): its specialist skills in developing anti-viral drugs means it has a key role to play in developing treatments for new viruses such as Covid-19. Gilead’s CEO also said any potential treatment would be affordable and accessible to all.
- **Thermo Fisher Scientific** (the world leader in serving medical science): it developed a key diagnostic test to detect nucleic acid from SARS-CoV-2. Its products were also used by scientists to find evidence that the virus is genetically stable and therefore a good target for a vaccine.

Covid-19 has also served to highlight the importance of strong government-funded healthcare systems which provide quality healthcare to all. This is particularly relevant in the US which has huge inequality in its healthcare provision, which could widen further as unemployment rises. This supports the expansion of US Medicaid, a federal and state programme that helps with medical costs for the elderly, disabled and those with low incomes. A core holding in the strategy, Centene, is the leading Medicaid-managed care provider and will play a vital role in expanding this programme to the broader population.

Technology has also played a key role during this pandemic. With lockdown, employees are forced to work from home.

Large cloud platform providers have had to meet the surge in demand for their services. A core holding in the strategy, Microsoft, has successfully done so, and not just for office workers but also students. My children have been successfully using Microsoft teams to conduct online lessons with their teachers and co-ordinate their learning. Governments have also been using such services to share Covid-19 dashboards with citizens and have provided key support to critical health and safety organisations such as first responders.

Improved levels of hygiene, meanwhile, have been critical in helping to slow the spread of Covid-19. Two of our holdings have played a key role here:

- **Ecolab** is a leading microbial control expert whose hygiene and sanitation solutions for commercial companies are key in supporting hygienic and healthy environments. Its solutions have helped ensure the environment for workers in essential services is clean and sanitary.
- **SGS SA** is an industrial inspection, testing and analysis services company. It is offering the services of its network of experts in health and safety, hygiene, disinfection monitoring, emergency planning, training and hazardous waste management to support businesses navigating this crisis.

¹ Columbia Threadneedle Investments, 1 April 2020.

² Mention of specific stocks is not a recommendation to deal.

To find out more visit
COLUMBIATHREADNEEDLE.COM



Important Information. For internal use by Professional and/or Qualified Investors only (not to be used with or passed on to retail clients). Past performance is not a guide to future performance. Your capital is at risk. The value of investments and any income is not guaranteed and can go down as well as up and may be affected by exchange rate fluctuations. This means that an investor may not get back the amount invested. This material is for information only and does not constitute an offer or solicitation of an order to buy or sell any securities or other financial instruments, or to provide investment advice or services. Where references are made to portfolio guidelines and features, these are at the discretion of the portfolio manager and may be subject to change over time and prevailing market conditions. Actual investment parameters will be agreed and set out in the prospectus or formal investment management agreement. Please note that the performance targets may not be attained. The analysis included in this document has been produced by Columbia Threadneedle Investments for its own investment management activities, may have been acted upon prior to publication and is made available here incidentally. Any opinions expressed are made as at the date of publication but are subject to change without notice and should not be seen as investment advice. Information obtained from external sources is believed to be reliable but its accuracy or completeness cannot be guaranteed. Any opinions expressed are made as at the date of publication but are subject to change without notice. Information obtained from external sources is believed to be reliable but its accuracy or completeness cannot be guaranteed. This document includes forward-looking statements, including projections of future economic and financial conditions. None of Columbia Threadneedle Investments, its directors, officers or employees make any representation, warranty, guaranty, or other assurance that any of these forward looking statements will prove to be accurate. The mention of any specific shares or bonds should not be taken as a recommendation to deal. This document and its contents are confidential and proprietary. The information provided in this document is for the sole use of those receiving the document. It may not be reproduced in any form or passed on to any third party without the express written permission of Columbia Threadneedle Investments. This document is the property of Columbia Threadneedle Investments and must be returned upon request. This document is not investment, legal, tax, or accounting advice. Investors should consult with their own professional advisors for advice on any investment, legal, tax, or accounting issues relating to an investment with Columbia Threadneedle Investments. This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors' with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparty and no other Person should act upon it. Issued by Threadneedle Asset Management Limited, registered in England and Wales, No. 573204. Registered Office: Cannon Place, 78 Cannon Street, London EC4N 6AG. Authorised and regulated in the UK by the Financial Conduct Authority. Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies.
columbiathreadneedle.com Issued 05.20 | J30592 | 3062873